Biotechnology

Sarepta Therap

Sarepta Therapeutics Inc. Exchanged Bonds via Private Agreement

Sarepta Therapeutics Receives Rating Advice from 30 Firms

Sarepta Therapeutics Inc. Refinances, Exchanging Notes for New Senior Notes and Adding Cash

Wedbush Gives Sarepta Therapeutics an Outperform Rating

Wells Fargo Analyst Maintains Buy Rating for Sarepta Therapeutics

Sarepta Therapeutics Receives FDA Approval to Administer ELEVIDYS Gene Therapy

Sarepta Therapeutics Updates Clinical Trial Progress for SRP-1003 for Type 1 Myotonic Dystrophy

Sarepta Updates Elevidys Prescribing Information to Address Liver Risks

U.S. Bank Securities and Citibank Maintain Sell Rating on Sarepta Therapeutics

FDA Approves Sarepta Therapeutics Gene Therapy Elevidys New Label

Quinn Opportunity Partners LLC Acquired Sarepta Therapeutics Shares in Q2

Mizuho Raises Sarepta Therapeutics' Stock Rating

Ear Recommends Healthcare Stocks

Ritu Baral gives Sarepta Therapeutics a hold rating

Gil Blum Issues Sell Rating for Sarepta Therapeutics

Sarepta Therapeutics released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 1.356 B and EPS of USD -2.713

Sarepta Therapeutics released FY2025 Q3 earnings on November 3 After-Market EST, actual revenue USD 399.36 M (forecast USD 337.03 M), actual EPS USD -1.8 (forecast USD -0.9384)

Sarepta Therapeutics Inc. Reports Q3 2025 Revenue and Outlines Clinical Progress

Amin Recommends Healthcare Stocks, Piper Sandler and Bank of America Securities Provide Ratings

Sarepta Therapeutics receives updated ratings from 29 analysts

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap